Associate Professor, Departments of Neurosurgery and Neurobiology and Anatomical SciencesMolecular Cancer TherapeuticsBS, Biology, 1979, University of MississippiPhD, Anatomy, 2006, University of Mississippi Medical Center
Contact information Department of Neurosurgery2500 N. State S., Room R732Jackson, MS 39216Pager: (601) 929-1343E-mail: firstname.lastname@example.org
The goal of the research is to develop and evaluate novel therapeutics for the treatment of malignant brain tumors. Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor. Current treatment strategy for patients with GBM includes surgery to remove as much of the tumor as possible combined with chemotherapy and radiation therapy. However, even with aggressive treatment, survival is poor. Therefore, alternative treatment strategies that can kill or slow tumor cells growth is necessary. Our laboratory is investigating new therapies for treating brain tumors. One, is using therapeutic polypeptides which consist of three components, an inhibitor (H1), a thermal responsive unit (ELP) and a cell penetrating peptide (CPP) unit. This therapeutic construct is delivered directly to the cytoplasm or nuclei of cells in the tumor mass. Another therapy is the use of CRAC channels inhibitors to treat brain tumors. CRAC channels have a role in tumor cell proliferation and metastasis. Finally, Studies have shown that tumor formation, growth, aggression and invasion are associated with a number of cellular products and abnormal cellular changes. These include, in part, the production of growth factors, cytokines, matrix metalloproteases and chromosomal abnormalities. However, few of the studies that have evaluated the presence of multiple molecular markers have correlated the findings with the clinical outcomes of patients. Our studies directly addresses the relationship of multiple tumor markers to patient's clinical outcomes.
2500 North State Street
Jackson, MS 39216